Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofersen in non-SOD1 ALS
NCT07294144Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of tofersen in amyotrophic lateral sclerosis (ALS), sponsored by Washington University School of Medicine. Started Dec 2025; status: recruiting.
02
Drugs
tofersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07294144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294144.